[1]李玲霞,张英民*.强的松联合缬沙坦治疗对特发性肺纤维化急性加重期患者血气指标、肺功能及运动耐量的影响观察▲[J].内科,2020,15(06):673-675+697.[doi:DOI：10.16121/j.cnki.cn45-1347/r.2020.06.11]
　LI Lingxia,ZHANG Yingmin.Effects observation of prednisone combined with valsartan on blood gas indexes, lung function and exercise tolerance in patients with acute exacerbation of idiopathic pulmonary fibrosis[J].Internal Medicine of China,2020,15(06):673-675+697.[doi:DOI：10.16121/j.cnki.cn45-1347/r.2020.06.11]
点击复制

强的松联合缬沙坦治疗对特发性肺纤维化急性加重期患者血气指标、肺功能及运动耐量的影响观察▲()
分享到：

《内科》[ISSN:1006-6977/CN:61-1281/TN]

卷:
15卷
期数:
2020年06
页码:
673-675+697
栏目:
论著
出版日期:
2020-12-31

文章信息/Info

Title:
Effects observation of prednisone combined with valsartan on blood gas indexes, lung function and exercise tolerance in patients with acute exacerbation of idiopathic pulmonary fibrosis
文章编号:
1673-7768（2020）06-0673-04
作者:
李玲霞; 张英民*
河南科技大学第一附属医院呼吸与危重症医学科，洛阳市471003
Author(s):
LI Lingxia;  ZHANG Yingmin
Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Henan University of Science and Technology, Luoyang 471003, Henan province, China
关键词:
特发性肺纤维化; 急性加重期; 强的松; 缬沙坦; 血气分析; 运动耐量
Keywords:
Idiopathic pulmonary fibrosis;  Acute exacerbation;  Prednisone;  Valsartan;  Blood gas analysis;  Exercise tolerance
分类号:
R 563
DOI:
DOI：10.16121/j.cnki.cn45-1347/r.2020.06.11
文献标志码:
A
摘要:
目的探讨强的松联合缬沙坦治疗对特发性肺纤维化急性加重期（AE-IPF）患者血气指标、肺功能及运动耐量的影响。方法选取2017年2月至2019年6月我院收治的AE-IPF患者84例，随机分为对照组和观察组，每组42例。对照组患者在常规治疗的基础上加服强的松治疗，观察组患者在对照组治疗的基础上加服缬沙坦治疗，疗程6个月。比较两组患者治疗前后的血气指标、肺功能及运动耐量（6分钟步行实验）变化情况。结果治疗6个月后，两组患者的动脉血氧分压（PaO2）、动脉血氧饱和度（SaO2）、用力肺活量（FVC）、一秒用力呼气容积（FEV1）、单次呼吸法一氧化碳弥散值（DLCO）及6分钟步行实验距离均显著提高，动脉血二氧化碳分压（PaCO2）均显著降低；观察组患者的PaO2、FVC、FEV1、DLCO及6分钟步行实验距离均大于对照组，PaCO2显著低于对照组，差异有统计学意义（P＜0.05）。结论强的松联合缬沙坦治疗可有效改善AE-IPF患者的血气指标，促进患者肺功能和运动耐量恢复。
Abstract:
ObjectiveTo explore the effects of prednisone combined with valsartan on blood gas indexes, lung function and exercise tolerance in patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF). MethodsA total of 84 AE-IPF patients admitted to our hospital from February 2017 to June 2019 were enrolled. They were randomly divided into control group and observation group, with 42 cases in each group. Patients in the control group additionally administrated prednisone based on the routine treatment, based on which the observation group administrated valsartan additionally, for a six-month treatment course. The blood gas indexes, lung function and exercise tolerance (a six-minute walking test) were compared between the two groups. ResultsAfter 6 months of treatment, the arterial partial pressure of oxygen (PaO2), arterial oxygen saturation (SaO2), forced vital capacity (FVC), forced expiratory volume in one second (FEV1), and diffusion capacity for carbon monoxide (DLCO), and the distances of the six-minute walking test significantly increased, and the partial pressure of carbon dioxide in the artery (PaCO2) significantly decreased. PaO2, FVC, FEV1, DLCO and the distances of the six-minute walking test in the observation group were larger or longer than those in the control group, and PaCO2 of the observation group was significantly lower than that of the control group, with statistically significant differences (P＜0.05). ConclusionPrednisone combined with valsartan can effectively improve blood gas indexes, promote the recovery of lung function and exercise tolerance in AE-IPF patients.

相似文献/References:

[1]杨瑾,李桂娟,常丽霞,等.慢性阻塞性肺疾病急性加重期和缓解期患者C反应蛋白检测结果分析[J].内科,2014,(05):564.
[2]刘波,陈林*,梁庆华.老年慢性阻塞性肺疾病急性加重期的病原菌及耐药性研究[J].内科,2012,(03):290.
　[J].Internal Medicine of China,2012,(06):290.
[3]杨瑾,王鸿雁,常丽霞,等.噻托溴铵联合克拉霉素治疗慢性阻塞性肺疾病急性加重期临床观察[J].内科,2016,(01):89.[doi:DOI：10.16121/j.cnki.cn45-1347/r.2016.01.33]
　[J].Internal Medicine of China,2016,(06):89.[doi:DOI：10.16121/j.cnki.cn45-1347/r.2016.01.33]
[4]朱世军,宋弘丽*,张伟安,等.特发性肺纤维化患者肺功能与CT表现相关性分析[J].内科,2016,(03):392.[doi:DOI：10.16121/j.cnki.cn45-1347/r.2016.03.18]
　[J].Internal Medicine of China,2016,(06):392.[doi:DOI：10.16121/j.cnki.cn45-1347/r.2016.03.18]
[5]陈雅玲,袁冰华,乔娇,等.循经法拍背配合机械振动排痰对急性加重期慢性阻塞性肺疾病患者的影响▲[J].内科,2017,12(04):547.[doi:DOI：10.16121/j.cnki.cn451347/r.2017.04.31]
　[J].Internal Medicine of China,2017,12(06):547.[doi:DOI：10.16121/j.cnki.cn451347/r.2017.04.31]
[6]叶伟杰,莫蝶仪.慢阻肺急性加重期与慢阻肺合并社区获得性肺炎患者临床表现对比分析[J].内科,2017,12(06):756.[doi:DOI：10.16121/j.cnki.cn45-1347/r.2017.06.09]
　YE Weijie,MO Dieyi.Comparison of clinical manifestations of patients with chronic obstructive pulmonary disease and patients with chronic obstructive pulmonary disease with community-acquired pneumonia[J].Internal Medicine of China,2017,12(06):756.[doi:DOI：10.16121/j.cnki.cn45-1347/r.2017.06.09]
[7]梁湛,李梁瑜,吴灏.穿心莲内酯联合纤维支气管镜灌洗治疗支气管扩张急性加重期患者临床疗效分析[J].内科,2018,13(02):185.[doi:DOI：10.16121/j.cnki.cn45-1347/r.2018.02.12]
　LIANG Zhan,LI Liangyu,WU Hao.Analysis of the clinical efficacy of andrographolide combined with fiberoptic bronchoscopy in the treatment of acute exacerbation of bronchiectasis[J].Internal Medicine of China,2018,13(06):185.[doi:DOI：10.16121/j.cnki.cn45-1347/r.2018.02.12]

备注/Memo

备注/Memo:
▲基金项目：河南省医学科技攻关计划资助项目（201602192）
*通信作者：张英民，河南科技大学第一附属医院呼吸与危重症医学科，电子邮箱 lt1857@163.com
更新日期/Last Update: 2021-01-11